Статья: Современные антигистаминные препараты в лечении аллергических заболеваний
14. KleineTebbe J., Josties C., Frank G. et ai. Inhibition of IgEmediated and IgEindependent histamine release from human basophil leukocytes in vitro by Hlantagonist, descarboethoxyloratadine. J. Allergy Clin. Immunol., 1994, 93, 494500.
15. Kreutner W., Hey J., Anthes J. et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine HI receptor antagonist, 1st communication: receptor selectivity, antihistaminic activity, and antiallergic effects. Arzneimittelforschung, 2000, 50, 345352.
16. KLreutner W., Hey J., Anthes J. et al. Preclinical studies of desloratadine, a nonsedating, selective histamine HI receptor antagonist with antiallergic activity. Allergy, 2000, 55 (suppl. 63), S278 (Abstract 997).
17. Kreutner W., Hey J., Chiu P., Barnett A. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine HIreceptor antagonist, 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelfoschung. 2000, 50 (5), 441448.
18. Lebel B., Bousquet J., Czarlewski W., CampbcU A. Loratadine reduces RANTES release by an epithelial cell line. J. Allergy Clin. Tmmunol., 1997, 99, (S444), Abstract 1802.
19. Lippert U., Moller A., Welker P. et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by HI and H2receptor antagonists. Exp. Dermatol., 2000, 9, 118124.
20. Lippert U., KrugerKrasagakes S., Moller A. el al. Pharmacological modulation of IL6 and IL8 secretion by the HIantagonist descarboethoxyloratadine and dexamethasone by human mast and basophilic cell lines. Exp. Dermatol., 1995, 4, 272276.
21. Lipworth B., Jackson C. Safety of inhaled and intranasal corticosteroids: lessons for the new millenium. Drug Saf., 2000, 23, 1133.
22. Lorber R., Salmun L., Danzig M. Desloratadine is effective at relieving nasal congestion, as demonstrated in three placebocontrolled trials in patients with seasonal allergic rhinitis. New Trends in Allergy V meeting, Davos, 2000. .
23. Molet S., Gosset P., Lasalle P. et al. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamineinduced activation of endothelial cells. Qm Exp. Allergy, 1997, 27, 11671174.
24. Nathan R. and the Desloradine Study Group. Desloratadine relieved nasal congestion in patients with seasonal allergic rhinitis. Annual meeting of American College of Allergy, Asthma and Immunology, Seattle, 2000.
25. Nayak A., Lorber R., Salmun L. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis. J. Allergy Clin. Immunol., 2000, 105 (1) Abstract 1122.
26. Norman P., Dimmann A., Rabasseda. Desloratadine: a preclinical and clinical overview. Drugs Today, 2001, 37 (4), 215227.
27. ODoj^iell B., Lawlor R., Simpson J. el al. The impact of chronic urticaria on the quality of life. Br. J. Dermatol., 1997, 136, 197201.
28. Pearlman D., Lumry W., Winder J., Noonan M. Oncedaily cetirizine effective in the treatment of seasonal allergic rhinitis: a randomized, doubleblind, placebocontrolled study. Clin. Pediatr. (Phila), 1997, 36. 209215.
29. Pedersen P., Weeke E. Asthma and allergic rhinitis in the same patients. Allercv, 1983, 38, 2529.
30. Premier B. and the Desloratadine Study Group. Desloratadine once daily reduces nasal congestion in patients with seasonal allergic rhinitis, 17th Int. Congress of Allergology and Clinical Immunology, Sydney, 2000.
31. Ratner P. and the Desloratadine Study Group. Desloratadine improved ASTHMA symptoms and reduced bronchodilatator use in 2 studies of patients with asthma and SAR. Ann. Meeting of American College of Allergy, Asthma in4 Immunology, Seattle, 2000.
32. Ring J., Hein R., Gauger A. Desloratadine in the treatment of chronic idiopathic urticaria. Allergy, 2001, 56 (suppl. 65), 2832. Bachcrt C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy, 2001, $6 (suppl. 65), 1420.
33. Schenkel E. and the Desloratadine Study Group. Desloratadine improved SAR symptoms in patients with mildtomoderate asthma and SAR. Ann. Meeting of American College of Allergy, Asthma and Immunology, Seattle, 2000.
34. Sibbald B., Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax, 1991, 46, 895901.
35. Vignota A., Crampette L., Mondain M. et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM1 and HLADR by nasal epithelial cells. Allergy, 1995, 50, 200203.
36. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISSAC International Study of Asthma and Allergies in Childhood Steering Committee. Lancety. 1998, 351 (9111), 12251232.
37. Young T., Finn L., Kom H. et al. Nasal obstruction as a risk factor for sleepdisordered breathing. J. Allergy Clin. Tmmunol., 1997, 99, S757S762.